- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02115646
Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary goal of the study will analyze whether the fractionated carbon dioxide laser can improve other subjective and objective qualities of hypertrophic and/or contracted burn scars with or without involvement of nearby mobile joints.
The investigators hypothesize that fractionated carbon dioxide laser therapy will increase range of motion and improve tissue compliance in all scars overlying a mobile joint that has been limited due to burn scar contracture. In addition, the investigators will evaluate the effect of fractionated carbon dioxide laser therapy on common sequelae of hypertrophic and/or contracted burn scars.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Shriners Hospital- Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males and females between 5 and 70 years of age with hypertrophic and/or contracted burn scars with or without involvement of mobile joints. The burn scars must have occurred at least 1 year prior to the date of enrollment.
- Having suitable areas of treatment: All wounds in the area of interest must be closed for at least two months, and the scars must be deemed stable for a period of 3 months before initiation of treatment.
- Fitzpatrick skin types I-VI
- Able and willing to comply with all visit, treatment and evaluation schedules and requirements
- Able to understand provide written informed consent
- Women of child-bearing age are required to be using a reliable method of birth control at least three months prior to study enrollment and throughout the course of the study.
Exclusion Criteria:
- Pregnant, intending to become pregnant during the course of the study, less than three months postpartum or less than six weeks after completion of breastfeeding.
- Active tanning, including the use of tanning booths, during the course of the study
- Showing symptoms of hormonal disorders (i.e.: uncontrolled thyroid disease or Polycystic Ovary Syndrome), as per the Investigator's discretion
- Abnormal photosensitivity due to metabolic disorder or due to use of external agents, (drugs, herbs, etc.) within 2 weeks of initial treatment or during the course of the study, except for use of aminolevulinic acid(Levulan®) which requires a washout period of three months
- Prior use of retinoids in treated areas within three months of initial treatment or during the course of the study
- Use of oral isotretinoin (Accutane®) within nine months of initial treatment or during the course of the study. Note: skin must retain its normal degree of moisture prior to treatment
- Prior skin treatment with laser or other devices in the treated area within three months of initial treatment or during the course of the study
- Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists
- History of collagen vascular disease
- Concurrent inflammatory skin conditions, including, but not limited to, rosacea of any severity
- Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment
- Multiple dysplastic nevi in area to be treated
- Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to each treatment (as per the patient's physician discretion)
- History of immunosuppression/immune deficiency disorders (including human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) or use of immunosuppressive medications
- Having any form of active cancer at the time of enrollment and during the course of the study
- Significant concurrent illness, such as uncontrolled diabetes, (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process)
- Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
- Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study
- If it is determined that the contracture is due to a deeper process involving the muscles, ligaments or bones.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: fractionated carbon dioxide laser
|
patients will have serial laser treatments
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Scar Pigmentation, Baseline vs 15-months
Time Frame: Baseline and 15 months
|
Using the colorimeter, will measure change in pigmentation of the scar at the conclusion of the study.
This tool measures the pigment in a scar, with a possible range of 0-100, with 100 being the darkest hyperpigmentation, and 0 being no hyperpigmentation.
|
Baseline and 15 months
|
Scar Elasticity, Baseline vs 15-months
Time Frame: Baseline and 15 months
|
This is the measure of the elasticity of the scar using a Torque-meter.
It is measured on a 0-1 unit scale, with 0 being normal skin elasticity and 1 being completely inelastic.
|
Baseline and 15 months
|
Scar Thickness
Time Frame: Baseline and 15 months
|
This is an ultrasound measurement using the Dermascan Cyberderm to measure the thickness of the scar at baseline in millimeters.
|
Baseline and 15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: Baseline and 15 months
|
The 36-Item Short Form Survey (SF-36) is a validated quality of life measurement tool.
It measures 8 health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.
It also includes a single item that provides an indication of perceived change in health.
It is scored on a 0-100 scale, with 100 being the least bothersome to quality of life.
|
Baseline and 15 months
|
POSAS
Time Frame: Baseline and 15 months
|
The Patient and Observer Scar Assessment Scale (POSAS) is a validated scale that measures both the patient assessment and the observer assessment on the quality (height, color, stiffness, thickness, symptoms, relief, surface area) of the scar.
Scores range from 0-60, with 60 being the worst quality of scar.
|
Baseline and 15 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011P001310
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn Scars
-
Bispebjerg HospitalCompleted
-
Castle Creek Biosciences, LLC.TerminatedRestrictive Burn ScarsUnited States
-
Castle Creek Biosciences, LLC.WithdrawnRestrictive Burn Scars of Joint AreaUnited States
-
Catalysis SLCompleted
-
Massachusetts General HospitalShriners Hospitals for ChildrenUnknownBurn ScarsUnited States
-
Association of Dutch Burn CentresCompletedBurns | ScarsNetherlands
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruitingBurn Scar | Scars, HypertrophicIndonesia
-
IBSA Farmaceutici Italia SrlDerming SRLCompletedAcne Scars - Mixed Atrophic and Hypertrophic | Ice Pick Scars | Rolling Scars | Boxcar ScarsItaly
-
University of ZurichUniversity Hospital, ZürichCompletedScars | Burn Injury | Soft Tissue Injury | Skin Necrosis | Congenital Giant Nevus | Skin TumorsSwitzerland
-
Medstar Health Research InstituteLatham FundRecruitingBurn Scar | Cicatrix | Scars | Cicatrix, Hypertrophic | Pigmentation Disorder | Scarring | Hypopigmented Skin | Hypopigmented Scar | Burns LaserUnited States
Clinical Trials on fractionated carbon dioxide laser
-
Qilu Hospital of Shandong UniversityRecruitingStress Urinary IncontinenceChina
-
Rambam Health Care CampusCompletedStress Urinary IncontinenceIsrael
-
Cairo UniversityCompleted
-
Rambam Health Care CampusRecruitingSexual DysfunctionIsrael
-
Zydolab - Institute of Cytology and Immune CytochemistryRuhr University of BochumRecruitingCondylomata AcuminataGermany
-
Sun Yat-sen UniversityRecruitingKeratosis | Eyelid Tumor | Pigmented Nevi | Xanthelasma PalpebrarumChina
-
Cairo UniversityCompleted
-
Henry Ford Health SystemCompletedHidradenitis SuppurativaUnited States
-
Moy-Fincher Medical GroupUnknown